Welcome to our dedicated page for Xilio Therapeutics SEC filings (Ticker: XLO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Xilio Therapeutics, Inc. filings document the regulatory record of a clinical-stage biotechnology company developing masked immuno-oncology therapies. Its 8-K reports cover financial results, pipeline and business updates, investor presentations, material agreements, capital-structure matters, and clinical or regulatory disclosures tied to its masked I-O programs.
Proxy statements and related 8-K filings describe stockholder votes, director elections, board and committee changes, auditor ratification, equity incentive plans, and amendments affecting common stock. The filing record also includes disclosures related to reverse stock split matters, security-holder rights, director compensation, and governance arrangements for the company’s Delaware corporate structure.
StemPoint Capital LP, StemPoint Capital Management GP LLC, and Michelle Ross report beneficial ownership of Xilio Therapeutics, Inc. common stock. The group may be deemed to beneficially own 628,866 shares of common stock through a combination of equity securities.
The position consists of 343,154 shares issuable upon exercise of pre-funded warrants, 142,856 shares underlying Series A Warrants, and 142,856 shares underlying Series C Warrants. These instruments are subject to a 9.99% Beneficial Ownership Limitation, which restricts exercise above that threshold.
Based on Xilio having 5,982,839 shares outstanding as of May 8, 2026, and including the warrant shares as required under Rule 13d-3(d)(1)(i), the reporting group may be deemed to hold 9.5% of the class. Voting and dispositive powers over all 628,866 warrant-based shares are reported as shared among the reporting persons.
Xilio Therapeutics reported higher collaboration and license revenue, driven by its partnerships with AbbVie and Gilead. Revenue rose to $18.7M for the quarter and $31.3M for the first half of 2026, compared with $8.1M and $11.0M a year earlier, mainly from AbbVie and Gilead milestones and service revenue.
Operating expenses were $22.2M for the quarter and $48.9M for the half, with research and development up year to date as programs advanced and general and administrative slightly lower. Net loss narrowed to $6.4M for the quarter and $15.9M for the half, versus $15.8M and $29.1M in 2025.
Xilio ended June 30, 2026 with $136.0M in cash and cash equivalents and expects this to fund operations for at least twelve months. Deferred revenue from AbbVie and Gilead totaled $35.3M, and common stock warrant liabilities were $30.2M. If all outstanding Series C warrants are exercised at $10.50, the company could receive up to $36.2M in additional gross proceeds in 2026.
Xilio Therapeutics reported second quarter 2026 results and key pipeline updates. Collaboration and license revenue for the quarter was $18.7 million, up from $8.1 million a year earlier, while net loss narrowed to $6.4 million from $15.8 million. Cash and cash equivalents were $136.0 million as of June 30, 2026, and total stockholders’ equity increased to $72.3 million from $35.3 million at year-end 2025.
Operationally, Xilio received FDA clearance of its IND for XTX501, a bispecific PD‑1 / masked IL‑2, enabling initiation of a Phase 1/2 trial in metastatic NSCLC and select solid tumors in the second half of 2026, with initial Phase 1 data in NSCLC planned in the second half of 2027. The company is advancing IND‑enabling studies for masked T cell engager programs targeting CLDN18.2 and PSMA+STEAP1, with IND submissions planned in the second half of 2027, and continues a Phase 2 trial of efarindodekin alfa.
Xilio expects its current cash to fund operations into the first quarter of 2028, excluding up to $36.2 million in potential Series C warrant proceeds and up to $31.0 million in potential near‑term milestones and option fees under its AbbVie collaboration.
Xilio Therapeutics director Bello Akintunde Olatokumbo received a grant of stock options for 5,000 shares of common stock. The options carry an exercise price of 7.99 per share and expire on June 10, 2036.
The award will vest as to 100% of the underlying 5,000 shares on the earlier of June 11, 2027 or Xilio Therapeutics’ next annual meeting of stockholders following the grant date, subject to his continued service. Following this grant, he holds 5,000 stock options, reflecting a routine compensation-related equity award rather than an open-market purchase or sale.
Xilio Therapeutics director Shannon James Samuel received a grant of stock options for 5,000 shares of common stock at an exercise price of $7.99 per share. These options vest 100% on the earlier of June 11, 2027 or the company’s next annual stockholder meeting, contingent on continued service.
Following the grant, Samuel holds 5,000 options directly.
Xilio Therapeutics director Daniel J. Curran received a grant of stock options covering 5,000 shares of common stock. The options have an exercise price of $7.99 per share and bring his total option holdings reported in this filing to 5,000 derivative shares.
The award was granted as of June 11, 2026 and will vest as to 100% of the underlying shares on the earlier of June 11, 2027 or the company’s next annual meeting of stockholders following the grant date, provided he continues to serve the company through the vesting date. This is a compensation-related grant rather than an open-market purchase or sale.
Xilio Therapeutics director Xu Yuan received a grant of stock options as equity compensation. The award covers 5,000 options to buy common stock at an exercise price of $7.99 per share, expiring on June 10, 2036.
The options were granted on June 11, 2026 and will vest in full on the earlier of June 11, 2027 or the company’s next annual stockholder meeting after the grant date, as long as Xu Yuan continues to serve the company through that vesting date. After this grant, the filing shows Xu Yuan holding 5,000 derivative securities (stock options).
Xilio Therapeutics director Robert W. Ross received a stock option grant covering 5,000 shares of common stock. The option has an exercise price of $7.99 per share and expires on June 10, 2036. It will vest in full on the earlier of June 11, 2027 or the company’s next annual stockholder meeting, assuming he remains in service. This is a compensation-related award, not an open-market share purchase or sale.
Xilio Therapeutics director Sara Bonstein received a grant of stock options covering 5,000 shares of common stock. The options have an exercise price of $7.99 per share and expire on June 10, 2036. They vest 100% on June 11, 2027 or at the next annual stockholder meeting, whichever occurs first, assuming continued service.
Xilio Therapeutics director Aoife Brennan received a new stock option grant. The award covers 5,000 shares of common stock at an exercise price of $7.99 per share, expiring on June 10, 2036. It vests 100% on June 11, 2027 or at the next annual stockholder meeting, subject to continued service.